Pharmacologic management of Parkinson disease: Treatment of levodopa-associated "wearing off"

Formulary

Volumn 41, Issue SUPPL., 2006, Pages 12-17

  Waters, Cheryl H ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TRIMETHOBENZAMIDE;

AKINESIA; AUTONOMIC NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; DYSKINESIA; FIRST PASS EFFECT; FOLLOW UP; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; LIVER FUNCTION; LIVER TOXICITY; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; SYNAPTIC MEMBRANE; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

EID: 33748508232     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448-458.
2. Kostic V, Przedborksi S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. 1991;41:202-205.
3. Waters CH. Managing the late complications of Parkinson's disease. Neurology. 1997;49(suppl 1):S49-S57.
4. Pahwa R, Lyons K, McGuire D, Dubinsky R, Hubble JP, Koller WC. Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. Neurology. 1996;46:1059-1062.
5. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord. 1994;9:40-47.
6. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179-1183.
7. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm Suppl. 1995;45:225-230.
8. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162-168.
9. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomized, multicentre study. J Neurol Neurosurg Psychiatry, 1999;66:436-441.
10. Weiner WJ, Factor SA, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord. 2001;7:115-120.
11. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology. 1997;49:1060-1065.
12. Pinter MM, Rutgers AW, Hebenstreit E. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease. J Neural Transm. 2000;107:1307-1323.
13. The Parkinson Study Group. Pramipexole vs levodopa as initial treament for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.
14. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol. 1996;19:234-245.
15. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology. 1998;51:1057-1062.
16. Rascol O, Brooks DJ, Korczn AD, et al. for the 065 Study Group. A five-year study in the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
17. Hutton JT, Metman LV, Chase TN, et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord. 2001;16:459-463.
18. Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol. 2001;24:163-169.
19. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinsons disease. Arch Neurol. 2003;60:1721-1728.
20. Hubble JP. Novel drugs for Parkinson's disease. Med Clin North Am. 1999;83:515-536.
21. Eldepryl® [Prescribing Information]. Tampa, Fla: Somerset Pharmaceuticals Inc; July 1998.
22. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;2:791-795.
23. Golbe LI, Lieberman AN, Meunter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol. 1988;11:45-55.
24. Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology. 1989;39:1109-1111.
25. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50:375-382.
26. Waters CH, Sethi KD, Hauser RA, et al; Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426-432.
27. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241-248.
28. Rascol O, Brooks DJ, Melamed E, et al, A comparative randomized study of rasagiline vs placebo or entacapone as adjunct to levodopa in Parkinson's disease (PD) patients with motor fluctuations (The LARGO Study). Neurology. 2004;62(suppl 5): A346. Abstract.
29. Parkinson Study Group. Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving other adjunctive therapy. Mov Disord. 2005;20(suppl 10):S138. Abstract P468.
30. Jorga K, Banken L, Fotteler B, Snell P, Steimer JL. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone. Clin Pharmacol Ther. 2000;67:610-620.
31. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. 1997;48:81-87.
32. DuPont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E; Tolcapone in Parkinson's Disease Study Group II (Tips II). Tolcapone added to levodopa in stable Parkinsonian patients: a double-blind placebo-controlled study. Mov Disord. 1997;12:928-934.
33. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology. 1997;49:665-671.
34. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol. 1998;55:1089-1095.
35. Koller W, Lees A, Doder M. Hely M; Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord. 2001;16:858-866.
36. Borges N. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf. 2003;26:743-747.
37. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000;59:1233-1250.
38. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 1997;42:747-755.
39. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998;51:1309-1314.
40. Poewe WH, Deuschl G, Gordin A, et al; Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo controlled double blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:245-255.
41. Brooks DJ, Sagar H; UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74:1071-1079.
42. Larsen JP, Worm-Petersen J, Siden A, et al; NOMESAFE Study Group. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol. 2003;10:137-146.
43. Hubble JP, Schumock GT, Markowitz J, Gutterman EM. Entacapone and quality-of-life in patients with Parkinson's disease: results of the Response Initiative Program. Neurol Rev. 2000;Oct(suppl):11-16.
44. Hubble JP, Schumock GT, Markowitz J, Gutterman EM. Entacapone and feelings of depression in patients with Parkinson's disease. Neurol Rev. 2000;Oct(suppl):17-20.
45. Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology. 2004;62 (suppl 1):S64-S71.
46. Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol. 1994;17:243-259.
47. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneotis apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990;53;96-101.
48. Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology. 2004;62(suppl 4):S12-S17.
49. Metman LV, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology. 1997;48:369-372.
50. Sherry JH, Guyton PJ, Van Lunen B, Bottini PB. Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease. Neurology. 2003;60(suppl 1):S09.005. Abstract.